IP Library Granted Patent US 7,910,617
Granted Patent B2
US 7,910,617 · App. 10/588,818 · Granted Mar 22, 2011

Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound

Assignee: Sankyo Company, Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,617
App. No.
10/588,818
Granted
Mar 22, 2011
Kind
B2
Abstract

A method for suppressing the number of peripheral blood lymphocytes involving administering to a human in need thereof a pharmaceutically effective amount of a compound which is (2R) -2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt thereof, such as the hydrochloride salt.

Claims (6)

1. A method for suppressing the number of peripheral blood lymphocytes comprising administering to a human in need thereof a pharmaceutically effective amount of a compound which is (2R) -2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt thereof.

2. The method according to claim 1 , wherein the pharmacologically acceptable salt is administered and the pharmacologically acceptable salt is a fumarate salt.

3. The method according to claim 2 , wherein the fumarate salt is orally administered to a human adult at a dose of 0.0001 mg/kg to 1 mg/kg.

4. The method according to claim 1 , wherein the compound is orally administered to a human adult at a dose of 0.0001 mg/kg to 1 mg/kg.

5. The method according to claim 1 , wherein the pharmacologically acceptable salt is administered and the pharmacologically acceptable salt is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol hydrochloride.

6. The method according to claim 5 , wherein the hydrochloride salt is orally administered to a human adult at a dose of 0.0001 mg/kg to 1 mg/kg.

Assignments (2)
MERGER Recorded Aug 10, 2011
From: SANKYO COMPANY, LIMITED
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 026724/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2006
From: NISHI, TAKAHIDE; TAKEMOTO, TOSHIYASU; MIYAZAKI, SHOJIRO; SHIMOZATO, TAKAICHI; NARA, FUTOSHI; IZUMI, TAKASHI
To: SANKYO COMPANY, LIMITED
Reel/Frame 018181/0646 →
Priority Claims (1)
JP 2004-048205 · Feb 24, 2004 · national
Continuity (1)
Related Publication 20070191468A1 · Aug 16, 2007